You are here: Industry Insights > opioid

News List

FDA Approves New Opioid for Intravenous Use in Hospitals, Other Clinical Settings americanpharmaceuticalreview
August 14, 2020
The U.S. Food and Drug Administration (FDA) approved Olinvyk (oliceridine), an opioid agonist for the management of moderate to severe acute pain in adults, where the pain is severe enough to require an intravenous opioid and for whom ...
US seeks nearly $13bn from Purdue Pharma over opioid claims pharmaceutical-technology
August 07, 2020
The US Department of Justice is seeking approximately $13bn in criminal and civil penalties from Purdue Pharma over opioid claims filed against the company.
Irisys to Manufacture BioCorRx's Opioid Use Disorder Treatment contractpharma
August 03, 2020
BICX102 can help prevent relapse following opioid detoxification.
FDA Recommends Discussing Naloxone When Prescribing Opioids, Opioid Use Disorder Treatments americanpharmaceuticalreview
July 28, 2020
To reduce the risk of death from opioid overdose, the U.S. Food and Drug Administration (FDA) is making the following recommendations about the opioid reversal medicine, naloxone.
FDA orders update of label change for opioid pain medications europeanpharmaceuticalreview
July 27, 2020
The FDA is requiring that labels for opioid pain medicine and medicines to treat opioid use disorder recommend healthcare professionals discuss the availability of naloxone with patients to reduce overdoses.
MindMed Initiates Dosing in Human Safety Study of Opioid Addiction Treatment americanpharmaceuticalreview
April 20, 2020
Mind Medicine has begun dosing the first subject in an additional Phase 1 human safety trial of 18-MC. The safety trial has commenced on time and as scheduled, even during the COVID-19 pandemic.
BMJ journal deems opioid dependency implant more favourable than tablets pharmatimes
March 30, 2020
A new benefit-risk study published in the BMJ Evidence Based Medicine has deemed a new implant preventing withdrawal symptoms for patients with opioid dependency more favourable than sublingual tablets.
MindMed Advances Potential Treatment for Opioid Addiction americanpharmaceuticalreview
March 30, 2020
Mind Medicine announced the company has begun enrollment in further human safety studies of 18-MC, the company's orally-active drug candidate for the treatment of opioid use disorders.
Mallinckrodt Provides Update on Proposed Global Opioid Settlement americanpharmaceuticalreview
March 12, 2020
Mallinckrodt announced New York State Attorney General Letitia James has joined 47 other state and U.S. Territory Attorneys General in supporting the previously announced proposed global opioid settlement with Mallinckrodt and related entities.
Mallinckrodt agrees to pay $1.6bn to settle opioid claims pharmaceutical-technology
March 04, 2020
Mallinckrodt has entered into a tentative agreement with 47 states, territories and lawyers in the US to pay $1.6bn to settle thousands of opioid-related lawsuits.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 21 22 Next page